NASDAQ:VRNA - VERONA PHARMA P/S Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding VERONA PHARMA P/S Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.55 -0.68 (-10.91 %) (As of 02/28/2020 01:51 PM ET) Add Compare Today's Range$5.35Now: $5.55▼$6.0050-Day Range$5.24MA: $6.24▼$7.2852-Week Range$3.65Now: $5.55▼$12.89Volume3,205 shsAverage Volume86,728 shsMarket Capitalization$73.09 millionP/E RatioN/ADividend YieldN/ABeta-0.77 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and II clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma, and allergic rhinitis. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VRNA Previous Symbol CUSIPN/A CIK1657312 Webhttp://www.veronapharma.com/ Phone44-20-3283-4200Debt Debt-to-Equity Ratio0.02 Current Ratio4.07 Quick Ratio4.07Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.40 per share Price / Book0.87Profitability EPS (Most Recent Fiscal Year)($2.02) Net Income$-26,560,000.00 Net MarginsN/A Return on Equity-50.99% Return on Assets-42.33%Miscellaneous Employees22 Outstanding Shares13,170,000Market Cap$73.09 million Next Earnings Date5/5/2020 (Estimated) OptionableNot Optionable Receive VRNA News and Ratings via Email Sign-up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:VRNA Rates by TradingView VERONA PHARMA P/S (NASDAQ:VRNA) Frequently Asked Questions What is VERONA PHARMA P/S's stock symbol? VERONA PHARMA P/S trades on the NASDAQ under the ticker symbol "VRNA." When is VERONA PHARMA P/S's next earnings date? VERONA PHARMA P/S is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for VERONA PHARMA P/S. What price target have analysts set for VRNA? 3 Wall Street analysts have issued twelve-month price targets for VERONA PHARMA P/S's stock. Their forecasts range from $17.00 to $60.00. On average, they expect VERONA PHARMA P/S's stock price to reach $37.00 in the next twelve months. This suggests a possible upside of 566.7% from the stock's current price. View Analyst Price Targets for VERONA PHARMA P/S. What is the consensus analysts' recommendation for VERONA PHARMA P/S? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VERONA PHARMA P/S in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for VERONA PHARMA P/S. Has VERONA PHARMA P/S been receiving favorable news coverage? Headlines about VRNA stock have trended very negative recently, InfoTrie reports. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. VERONA PHARMA P/S earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for VERONA PHARMA P/S. Are investors shorting VERONA PHARMA P/S? VERONA PHARMA P/S saw a decrease in short interest in the month of January. As of January 31st, there was short interest totalling 84,300 shares, a decrease of 51.0% from the January 15th total of 171,900 shares. Based on an average daily volume of 231,400 shares, the days-to-cover ratio is presently 0.4 days. Currently, 1.1% of the shares of the stock are short sold. View VERONA PHARMA P/S's Current Options Chain. Who are some of VERONA PHARMA P/S's key competitors? Some companies that are related to VERONA PHARMA P/S include Albireo Pharma (ALBO), Minerva Neurosciences (NERV), Evolus (EOLS), Evofem Biosciences (EVFM), Osmotica Pharmaceuticals (OSMT), Aduro BioTech (ADRO), Syros Pharmaceuticals (SYRS), Spectrum Pharmaceuticals (SPPI), OptiNose (OPTN), MannKind (MNKD), Kamada (KMDA), AMAG Pharmaceuticals (AMAG), Gemphire Therapeutics (GEMP), Seres Therapeutics (MCRB) and Bicycle Therapeutics (BCYC). What other stocks do shareholders of VERONA PHARMA P/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other VERONA PHARMA P/S investors own include Ligand Pharmaceuticals (LGND), Novavax (NVAX), Sorrento Therapeutics (SRNE), Supernus Pharmaceuticals (SUPN), Teva Pharmaceutical Industries (TEVA), Galmed Pharmaceuticals (GLMD), Inovio Pharmaceuticals (INO), SUMMIT THERAPEU/S (SMMT), Viking Therapeutics (VKTX) and Cara Therapeutics (CARA). Who are VERONA PHARMA P/S's key executives? VERONA PHARMA P/S's management team includes the folowing people: Dr. Jan-Anders Karlsson, CEO & Exec. Director (Age 64)Mr. Piers John Morgan, Chief Financial Officer (Age 53)Ms. Claire Louise Poll L.C.S.W., B.A., B Juris, LLB, ASIA, Gen. Counsel (Age 52)Ms. Victoria Stewart, Director of CommunicationsDr. Peter Spargo, Sr. VP of Chemistry Manufacturing & Controls (Age 57) When did VERONA PHARMA P/S IPO? (VRNA) raised $61 million in an initial public offering (IPO) on Thursday, April 27th 2017. The company issued 4,500,000 shares at a price of $13.49 per share. Jefferies and Stifel served as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers. Who are VERONA PHARMA P/S's major shareholders? VERONA PHARMA P/S's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Wedbush Securities Inc. (0.62%), Renaissance Technologies LLC (0.09%) and UBS Group AG (0.08%). Which institutional investors are buying VERONA PHARMA P/S stock? VRNA stock was purchased by a variety of institutional investors in the last quarter, including Wedbush Securities Inc., Renaissance Technologies LLC and UBS Group AG. How do I buy shares of VERONA PHARMA P/S? Shares of VRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is VERONA PHARMA P/S's stock price today? One share of VRNA stock can currently be purchased for approximately $5.55. How big of a company is VERONA PHARMA P/S? VERONA PHARMA P/S has a market capitalization of $73.09 million. The company earns $-26,560,000.00 in net income (profit) each year or ($2.02) on an earnings per share basis. VERONA PHARMA P/S employs 22 workers across the globe.View Additional Information About VERONA PHARMA P/S. What is VERONA PHARMA P/S's official website? The official website for VERONA PHARMA P/S is http://www.veronapharma.com/. How can I contact VERONA PHARMA P/S? VERONA PHARMA P/S's mailing address is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. The company can be reached via phone at 44-20-3283-4200 or via email at [email protected] MarketBeat Community Rating for VERONA PHARMA P/S (NASDAQ VRNA)Community Ranking: 3.4 out of 5 ( )Outperform Votes: 252 (Vote Outperform)Underperform Votes: 114 (Vote Underperform)Total Votes: 366MarketBeat's community ratings are surveys of what our community members think about VERONA PHARMA P/S and other stocks. Vote "Outperform" if you believe VRNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRNA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/28/2020 by MarketBeat.com StaffFeatured Article: What is the outlook for the FAANG stocks?
